After being publicly skewered by Sen. Bernie Sanders (I-Vt.) over the $375,000 price tag for its rare disease drug, Catalyst Pharmaceuticals released a lengthy response defending the steps being taken to ensure the medicine is accessible to patients.

In a six-page letter, the company tried to strike a respectful tone while challenging some of the assertions made by Sanders, who earlier this month accused Catalyst of “fleecing” Americans and “immoral exploitation” by setting a “staggering” price. In doing so, he helped catapult the drug, which treats a rare neuromuscular disorder, into the contentious national debate over the cost of medicines.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • No reason he should be mollified. Catalyst is despicable. Had Jacobus gotten approval, they would doubtless have charged more than nothing, but hopefully not this sort of price.

    If they spent “millions of dollars,” it won’t take many patients at all to recoup that from public monies and insurance premiums we all end up paying the price for. And then it’s all gravy.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy